Valuation: Appili Therapeutics Inc.

Market Cap 1.99M 1.4M 1.22M 1.13M 1.05M 132M 2.03M 13.59M 5.25M 65.17M 5.25M 5.13M 226M P/E 2025
-1.62x
P/E 2026 -0.44x
Enterprise Value 14.88M 10.47M 9.17M 8.47M 7.91M 990M 15.22M 102M 39.33M 488M 39.33M 38.47M 1.7B EV / Sales 2025
152,429,607x
EV / Sales 2026 60,946,081x
Free-Float
99.94%
Yield 2025 *
-
Yield 2026 -
06-27 Appili Therapeutics Inc. Reports Earnings Results for the Full Year Ended March 31, 2026 CI
02-18 Appili Therapeutics announces closing of second tranche of non-brokered private placement RE
02-12 Appili Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025 CI
12-18 Appili Therapeutics closes first tranche of non-brokered private placement RE
12-15 The Lundquist Institute and Vitalex Biosciences Announces Strategic Advancement of Second-Generation fungal Vaccine VXV-01 through Phase 1 Trials under $40 Million Competitive Contract from NIH/NIAID CI
11-13 Appili Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2025 CI
11-13 Appili Therapeutics Brief: On LIKMEZ (ATI-1501), Says "Building Commercial Momentum in the U.S. Through Re-Launch and Increasing Sales Growth" MT
11-13 Appili Therapeutics Brief: Citing New NIAID Non-Dilutive Funding Award of Up to US $40 Million with US$90 Million in Pending Proposals Across Multiple Infectious Disease Programs MT
11-13 Appili Therapeutics Brief: Reported a Q2 Net and Comprehensive Loss of $1.0 million ($0.01 per share) MT
11-05 Appili Therapeutics Announces $750,000 Private Placement for Working Capital, Drug Development MT
11-05 Appili Therapeutics announces proposed non-brokered private placement RE
11-05 Appili Therapeutics Brief: Announcing Proposed Non-Brokered Private Placement MT
11-04 Appili Therapeutics Inc. announced that it expects to receive CAD 0.75 million in funding CI
3 months-25.00%
6 months-40.00%
Current year-40.00%
1 week 0.01
Extreme 0.01
0.02
1 month 0.01
Extreme 0.01
0.02
Current year 0.01
Extreme 0.01
0.02
1 year 0.01
Extreme 0.01
0.04
3 years 0.01
Extreme 0.01
0.08
5 years 0.01
Extreme 0.01
1.14
10 years 0.01
Extreme 0.01
1.89
Manager TitleAgeSince
Chief Executive Officer 65 2022-10-31
Director of Finance/CFO 68 2021-11-15
Corporate Officer/Principal - -
Director TitleAgeSince
Chairman 50 2015-05-06
Director/Board Member 58 2018-09-30
Chairman 59 2022-11-12
Date Insider Type Main position Quantity % Market Cap.
25-07-15Option

Director

1,189,580 0.9810%
25-07-15Option

Director

1,189,580 0.9810%
25-07-15Option

Director

128,674 0.1061%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00%0.00%-62.50% 1.4M
+0.13%-1.33%+63.86%+121.93% 55.63B
+6.76%+18.10%+91.66%+104.09% 52.25B
+3.33%+4.51%-11.68%-11.91% 23.07B
+1.32%+6.22%+5.28%+415.45% 22.41B
+0.97%+3.81%+31.23%-32.21% 15.94B
-0.89%+5.71%+24.30%+186.29% 13.77B
+9.96%+15.98%+157.65%+310.89% 13.47B
+2.85%+2.81%+75.32%+139.44% 11.82B
+6.17%+10.22%+163.15%+166.44% 11.16B
Average +3.06%+6.68%+60.08%+133.79% 21.95B
Weighted average by Cap. +3.22%+7.52%+63.13%+141.22%

Financials

2025 2026
Net sales 0.1 0.07 0.06 0.06 0.05 6.68 0.1 0.69 0.27 3.3 0.27 0.26 11.45 0.24 0.17 0.15 0.14 0.13 16.25 0.25 1.67 0.65 8.02 0.65 0.63 27.83
Net income -2.62M -1.85M -1.62M -1.49M -1.39M -175M -2.68M -17.97M -6.94M -86.16M -6.94M -6.78M -299M -4.24M -2.98M -2.61M -2.41M -2.25M -282M -4.34M -29.03M -11.21M -139M -11.21M -10.96M -483M
Net Debt 11.07M 7.79M 6.82M 6.3M 5.88M 736M 11.32M 75.76M 29.25M 363M 29.25M 28.61M 1.26B 12.9M 9.08M 7.95M 7.34M 6.85M 858M 13.19M 88.28M 34.08M 423M 34.08M 33.34M 1.47B
Logo Appili Therapeutics Inc.
Appili Therapeutics Inc. is a Canada-based biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures. The Company is advancing a diverse range of anti-infectives, including an FDA-approved ready-made suspension of metronidazole for the treatment of antimicrobial-resistant infections, a vaccine candidate to eliminate a serious biological weapon threat, and a topical antiparasitic for the treatment of a disfiguring disease. Its anti-infective product development portfolio includes three programs: LIKMEZ (ATI-1501), ATI-1701, and ATI-1801. ATI-1501 is its advanced commercial stage asset, a liquid oral taste-masked reformulation of the antibiotic metronidazole. ATI-1701 is a novel, live-attenuated vaccine for Francisella tularensis (F. tularensis). ATI-1801 is a novel topical formulation of paromomycin (15% w/w) under advanced clinical development for the treatment of cutaneous leishmaniasis, a disfiguring infection of the skin.
Employees
7
Date Price Change Volume
26-06-29 $0.0150 0.00% 37,010
  1. Stock Market
  2. Stocks
  3. APLI Stock